Microdosing involves taking tiny amounts of psychedelic substances in order to produce subtle changes in cognitive function without altering perception. Although many underground adherents attribute a variety of psychological and physical benefits to
With the Beckley/Maastricht Programme, we are conducting a series of placebo-controlled
Outside of the lab, the Beckley/Imperial team are also conducting the world’s first placebo-controlled, self-blinded study of
Amanda Fielding is also working on a new collaboration with researchers in the San Francisco Bay area to investigate the new Silicon Valley microdosing trend.
Results from our studies will provide robust scientific data to a worldwide conversation currently dominated by speculation and anecdote, and so identify or confirm the potential benefits of microdosing and pave the way for the development of clinical trials investigating its therapeutic applications in more depth.
With little or no inclination for governments or pharmaceutical companies to finance research into psychedelic medications, studies such as this depend entirely on private donors and institutions.
Given our current understanding of the mechanisms of action of psychedelic compounds such as LSD, possible future indications for microdosing could include a range of conditions in need of more efficient treatments such as mood disorders, age-related cognitive decline/mild cognitive impairment, chronic pain, brain rehabilitation and addiction. The Beckley Foundation is aiming to initiate research projects exploring these potential therapeutic applications.
If you want to get involved and make this important line of research a reality, please consider donating to help fund this and other studies into the potential health benefits of psychedelic compounds.
Psilocybin for Depression
Type of publication